Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials

Affiliations

• ¹ Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; The George Institute for Global Health, University of New South Wales, Sydney, Australia; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
• ² Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
• ³ The George Institute for Global Health, University of New South Wales, Sydney, Australia.
• ⁴ NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
• ⁵ The George Institute for Global Health, University of New South Wales, Sydney, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
• ⁶ Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA.
• ⁷ British Heart Foundation (BHF) Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.